CDK4 and lymphoma: In fact, recent results from the NCI-MATCH trial, which included a sub-study to assess palbociclib in patients with solid tumors or lymphomas harboring at least seven copies of CDK4 or CDK6, found that only 1 of 38 patients had a partial response, 10 had stable disease, and 21 experienced disease progression, with responses occurring only in CDK4-amplified (but not CDK6-amplified) cases.